New drug cocktail shows promise for tough lung cancer cases

NCT ID NCT06029127

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new drug called gimistotug (BGB-A445) combined with either another experimental drug (BGB-15025) or the standard chemo docetaxel in 35 people with advanced non-small cell lung cancer. All participants had already tried an immunotherapy and chemotherapy. The main goal was to see if the combinations could shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gimistotug (BGB-A445) plus BGB-15025 or docetaxel
What this could lead to: If successful, this could point toward a new combination treatment option for people with non-small cell lung cancer whose disease has progressed after standard therapy.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Affiliated Hospital of Jiangnan University South Campus

Wuxi, Jiangsu, 214122, China
Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China
Daping Hospital, Third Military Medical University

Chongqing, Chongqing Municipality, 400042, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200000, China
Gansu Provincial Hospital

Lanzhou, Gansu, 730000, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
Henan Cancer Hospital

Zhengzhou, Henan, 450000, China
National Cancer Center

Goyang-si, Gyeonggi-do, 10408, South Korea
Severance Hospital Yonsei University Health System

Seoul, Seoul Teugbyeolsi, 03722, South Korea
Shanxi Provincial Cancer Hospital

Taiyuan, Shanxi, 030013, China
The Catholic University of Korea, St Vincents Hospital

Suwon, Gyeonggi-do, 16247, South Korea
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

Guangzhou, Guangdong, 510405, China
The First Affiliated Hospital of Nanchang University Branch Donghu

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Shandong First Medical University

Taian, Shandong, 271099, China
The Second Xiangya Hospital of Central South University

Changsha, Hunan, 410011, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
Weihai Municipal Hospital

Weihai, Shandong, 264299, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.